^
Association details:
| Biomarker: | EGFR A767dupASV |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rybrevant (amivantamab-vmjw) (EGFR inhibitor, c-MET inhibitor) + Exkivity (mobocertinib) (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Enhanced in Vivo Efficacy of Mobocertinib and Amivantamab Combination in EGFR ex20ins+ NSCLC PDX Models
Published date:
08/08/2023
Excerpt:
The combined efficacy of mobocertinib and amivantamab was tested in 2 human patient-derived xenograft (PDX) models expanded from patients with EGFR ex20ins+ NSCLC, namely CTG-2842 (EGFR A767dupASV) and J100672 (EGFR S768dupSVD)….in the CTG-2842 model, combined dosing of amivantamab at 3, 10, and 30 mg/kg with a suboptimal dose of mobocertinib at 7.5 mg/kg showed enhanced benefit versus mobocertinib alone, with 95%, 153%, 231% GRI, respectively, and corresponding synergy scores of -58 (P=0.012), -111 (P <0.001), -200 (P <0.001).
